Auropharma Q4 FY26 Results Analysis: Margin Compresses 124 bps, Deleveraging Continues

AUROPHARMA's Q4 FY26 numbers came in mixed, with revenue of Rs. 8,853.34 Cr (+5.60% YoY) and PAT growth of +2.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Aurobindo delivered FY26 results in-line with guidance at the lower end (EBITDA margin 20.15% vs 20-21% target, revenue +6.1% vs high single-digit guidance). Strong cash conversion (CFO/PAT 1.58x) and deleveraging (D/E 0.19x) demonstrate solid execution, but margin compression (124 bps YoY) from cost pressures and elevated expenses is a concern. Key near-term catalysts include biosimilar US filing (Q2/Q3 CY2026), Eugia III reinspection clearance, and CDMO revenue ramp in FY27. The stock is trading in-line with guidance with limited alpha drivers in the immediate term.

Key Investment Insights

Key Positives

• Revenue grew 5.6% YoY to Rs.88,533 Mn, meeting management's high single-digit growth guidance
• CFO/PAT ratio of 1.58x indicates excellent cash conversion quality
• Debt/Equity improved to 0.19x from 0.23x; non-current borrowings eliminated
• Net worth grew 10.6% YoY to Rs.2,27,177 Mn standalone
• ROCE improved to 16.18% from 12.63%; ROE improved to 10.81% from 8.76%
• Other operating income surged 10,084% YoY from product approvals and milestone income

Risk Factors

• EBITDA margin compressed 124 bps YoY to 19.76%; full-year at 20.15% at lower end of 20-21% guidance
• Total expenses grew 7.4% YoY exceeding revenue growth of 5.6% — margin compression visible
• Employee costs grew 18.2% YoY; purchase of stock-in-trade surged 46.3% YoY
• Unit-II (Eugia Bhiwadi) classified OAI by US FDA — injectables recovery still pending
• API segment under pressure at -4.3% YoY in Q3; pricing headwinds persist
• Working capital consumed Rs.14,998 Mn in inventories — significant lock-up